Clinical Trial Update: A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the effects of switching from emicizumab to marstacimab in people with severe hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)
• Marstacimab (Marstacimab)

Snippet

Sponsor: Pfizer | Conditions: Severe Hemophilia A | Phase 1 | Status: RECRUITING